A Canadian biotechnology company has used cystic fibrosis patient tissue to grow “organoids” in a lab in order to use them to study the disease and test patients’ response to therapies.
The company has worked for 20 years on organoid technology, developing new tools to deliver robust and reliable organoids that can model human diseases.
“The development of organoid culture techniques has expanded the limits of what scientists can accomplish in vitro. At Stemcell, we are committed to providing tools for culturing organoids to researchers across the globe,” Allen Eaves, founder and chief executive officer of Stemcell Technologies, said in a press release.
